Stay updated on Pembrolizumab Combo in Metastatic NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Metastatic NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Metastatic NSCLC Clinical Trial page
- Check6 days agoNo Change Detected
- Check14 days agoChange DetectedAdded Lung cancer and related topics, including MedlinePlus Genetics, and updated the page revision to v3.4.2. Removed the government funding lapse notice and the previous revision v3.4.1; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check21 days agoChange DetectedAdded a government funding notice about potential delays and updated the page revision to v3.4.1; the previous revision v3.4.0 was removed.SummaryDifference0.2%

- Check28 days agoChange DetectedRemoved core topic labels like 'Lung cancer' and related topics, affecting the trial's disease focus and discoverability. Added UI elements such as 'Show glossary' and QC-related metadata like 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0'.SummaryDifference0.2%

- Check35 days agoChange DetectedAdded 'Lung cancer' as a related topic and a MedlinePlus Genetics link under Related Topics. These additions improve discoverability without altering study details or results.SummaryDifference0.1%

- Check42 days agoChange DetectedRevision: v3.3.4 was added; Lung cancer and related topics (MedlinePlus Genetics) were removed, along with Revision: v3.3.3.SummaryDifference0.1%

- Check49 days agoChange DetectedAdded related topics: Lung cancer and MedlinePlus Genetics to the page to link to broader information.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Combo in Metastatic NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Metastatic NSCLC Clinical Trial page.